Gilead’s Kite gains some height after second CAR-T approval in US

Gilead’s Kite gains some height after second CAR-T approval in US

Source: 
Pharmaforum
snippet: 

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T therapy could claw back some value.